Cardiopulmonary Stress Testing Systems Market - Growth, Trends, and Forecasts (2022 - 2027)

The Cardiopulmonary Stress Testing Systems Market studied was anticipated to grow with a CAGR of nearly 4.6%, during the forecast period. The major factors attributing to the growth are a rise in the global prevalence of multiple cardiovascular indications and atrial fibrillation necessitating the evaluation of Cardiopulmonary functioning. For instance, according to Global Health And Wellness Report - 2018, about 40% of the adult population in the United States have been diagnosed with a cardiovascular condition in 2018 demanding the adoption of stress testing procedures for early diagnosis of heart diseases driving the market growth throughout the forecast period.

Key Market Trends

Exercise Testing Systems are Expected to Hold the Largest Market Share

• The Exercise Testing Systems attributes the largest share in the market owing to the accuracy and the least operating time taken by these devices. Furthermore, the increased preference by the physicians and patients due to their cost-effectiveness and multiple applications of these devices also contribute to the rise in the adoption of these systems fueling the growth of the market.
• Based on the end-users, the hospital segment is expected to dominate the cardiopulmonary stress testing systems market. Dominance is due to the preference of patients for the early diagnosis of cardiovascular diseases as prescribed by physicians. The diagnostic centers are likely to witness the highest growth due to the adoption of advanced technologies in the developed countries driving the global cardiopulmonary stress testing systems market over the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period.

North America is expected to dominate the global cardiopulmonary stress testing (CPST) systems market throughout the forecast period. The dominance is due to the rising prevalence of cardiovascular and pulmonary disorders such as arrhythmia, heart failures, ischemic heart disease, dyspnea and heart valve imbalance in the United States which generates higher demand for the CPST. For instance, according to the Journal of American Medical Association report - 2018, about 93.3 million adults over the age of 20 in the United States were obese which is the major cause for cardiopulmonary diseases driving the market growth in the forecast period. Also, increasing incidences of lifestyle diseases and enhanced awareness among the medical professionals about the advantages of CPST along with the availability of advanced healthcare infrastructure in the region contributes to its outstanding share in the global market revenue.

Competitive Landscape

The cardiopulmonary stress testing systems market is moderately competitive and consists of several major players. In terms of market revenue, few of the prominent players currently dominating the market are vigorously making acquisitions with the other companies to consolidate their market positions across the globe and while others are launching new products. For example, in August 2019, Vyaire Medical Inc received FDA clearance for its two Novel Pulmonary Function Testing Products Vyntus ONE and Vyntus BODY, expanded their existing Vyntus products portfolio which runs on the easy-to-operate SentrySuite Software. The approved products offer a modern ergonomic design, consistent and accurate respiratory testing attracting the attention of customers in the U.S. Healthcare contributing to the market growth. Some of the companies which are currently dominating the market are Koninklijke Philips N V, Hillrom Services Inc, General Electric Company, MGC Diagnostics Corporation, OSI Systems Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support